Journals A-Z
All Subjects
Free Journals
sciepub.com
American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: https://www.sciepub.com/journal/ajidm Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
Go
Issue 4, Volume 4
Article Metrics
  • 42500
    Views
  • 40792
    Saves
  • 0
    Citations
  • 9
    Likes
Export Article
American Journal of Infectious Diseases and Microbiology. 2016, 4(4), 79-90
DOI: 10.12691/ajidm-4-4-3
Open AccessReview Article

Re-Emerging Human Viral Hemorrhagic Fevers: A Review

Joshua B. Owolabi1, , Chinenye M. Mamah1, Cynthia C. Okoro1 and Chinemerem A. Iheanacho1

1Department of Microbiology & Immunology, All Saints University College of Medicine, Kingstown, St. Vincent & the Grenadines

Pub. Date: September 22, 2016
View Full Text Full Text PDF (520 KB) Full Text ePUB(1882 KB)

Cite this paper:
Joshua B. Owolabi, Chinenye M. Mamah, Cynthia C. Okoro and Chinemerem A. Iheanacho. Re-Emerging Human Viral Hemorrhagic Fevers: A Review. American Journal of Infectious Diseases and Microbiology. 2016; 4(4):79-90. doi: 10.12691/ajidm-4-4-3

Abstract

The explosive introduction of Chikungunya in the Caribbean and imported cases in the United States, the rapid spread of Ebola in West Africa, the clusters of birth defects linked to an epidemic of Zika virus in the Americas, and the increasing endemic spread in parts of West Africa and recent imported cases of Lassa fever in the United Kingdom and Germany illustrate how quickly local outbreaks of infectious diseases can become threats to international public health. Unfortunately, with the exception of a few, there are no drugs or vaccines available for treatment or prevention of re-emerging human viral hemorrhagic infections, thus, surveillance remains the best approach for the early detection of outbreaks. Although, molecular diagnostics continues to evolve very rapidly, and its impact in the diagnosis of infectious viral diseases is undeniable, multiple challenges still remain for the widespread use of cost-effective, validated, and commercially available molecular tools. In this review, we briefly describe the epidemiology and global expansion of selected re-emerging hemorrhagic fever viruses in recent years, then focus on the clinical features and the laboratory testing for the diseases. In particular, we reflect on new learnings during recent outbreak investigations, discuss ongoing research and development priorities and identify further interventions needed for effective control and prevention of these re-emerging viral diseases.

Keywords:
Chikungunya Ebola Lassa Zika global health security

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 8

References:

[1]  Fauci, A. S., Morens, D. M., “The perpetual challenge of infectious diseases.” N Engl J Med 366: 454-461. Feb. 2012.
 
[2]  Morse, S. S., Hughes, J. M., “Developing an integrated epidemiologic approach to emerging infectious diseases.” Epidemiol Rev 18: 1-3. Feb. 1996.
 
[3]  Olano, J. P., Walker, D. H., “Diagnosing emerging and reemerging infectious diseases. The pivotal role of the pathologist.” Arch Pathol Lab Med 135: 83-91. Jan. 2011.
 
[4]  Dong, J., Olano, J. P., McBride, J. W., Walker, D. H., “Emerging pathogens: Challenges and successes of molecular diagnostics.” JMD 10(3): 185-197. May 2008.
 
[5]  Cleri, D. J., Ricketti, A. J., Porwancher, R. B., Ramos-Bonner, L. S., Vernaleo, J. R., “Viral hemorrhagic fevers: Current status of endemic disease and strategies for control.” Infect Dis Clin North Am 20: 359-393. Jun. 2006.
 
[6]  Bowen, M. D., Peters, C. J., Nichol, S. T., “Phylogenetic analysis of the Arenaviridae: Patterns of virus evolution and evidence for co-speciation between arenaviruses and their rodent hosts.” Mol Phylogenet Evol 8: 301-316. Dec. 1997.
 
[7]  Frame, J. D., Baldwin, J. M., Gocke, D. J., Troup, J. M., “Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.” Am J Trop Med Hyg 19(4):670-676. Jul. 1970.
 
[8]  Swiss Institute of Bioinformatics, “Viralzone: Arenavirus” Sep. 2016. Available: http://viralzone.expasy.org/viralzone/all_by_species/83.html [Accessed Sep. 15 2016].
 
[9]  Lukashevich, I.S. Salvato, M.S. “Lassa Virus Genome.” Current Genomics 7: 351-379. Sep. 2006.
 
[10]  Demby, A. H., Inapogui, A., Kargbo, A., Koninga, J., Kourouma, K., et al., “Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals.” Vector Borne Zoonotic Dis 1(4):283-297. Dec. 2001.
 
[11]  Atkin, S., Anaraki, S., Gothard, P., Walsh, A., Brown, D., Gopal, R., Hand, J., Morgan, D., “The first case of Lassa fever imported from Mali to the United Kingdom, February 2009.” Euro Surveill 14(1):19145. Mar. 2009.
 
[12]  Sogoba, N., Feldmann, H., Safronetz, D., “Lassa fever in West Africa: Evidence for an expanded region of endemicity.” Zoonoses Public Health 2: 43-47. Sep. 2012.
 
[13]  Günther, S., Emmerich, P., Laue, T., Kühle, O., Asper, M., Jung, A., Grewing, T., ter Meulen, J., Schmitz, H., “Imported Lassa Fever in Germany: Molecular characterization of a new Lassa virus strain.” Emerg. Infect. Dis. 6(5): 466-476. Sep. 2000.
 
[14]  World Health Organization, “WHO calls for early diagnostic tests for Lassa fever.” Emergencies preparedness, response Apr. 2016. Available: http://www.who.int/csr/disease/lassafever/early-diagnostic-lassa-fever/en/. [Accessed May 20, 2016].
 
[15]  World Health Organization, (2012) “Lassa fever in Nigeria.” Global alert and response, Apr. 2012. Available: http://www.who.int/csr/don/2012_04_04/en/. [Accessed May 20, 2016].
 
[16]  Ogbu, O., Ajuluchukwu, E, Uneke, C. J. “Lassa fever in West African sub-region: An overview.” J Vect Borne Dis 44: 1-11. Mar. 2007.
 
[17]  Cummins, D., Bennett, D., Fisher-Hoch, S. P., Farrar, B., Machin, S. J., McCormick, J. B., “Lassa fever encephalopathy: Clinical and laboratory findings.” J Trop Med Hyg 95: 197-201. Jun. 1992.
 
[18]  Cummins, D., McCormick, J. B., Bennet, D., Samba, J. A., Farrar, B., Machin, S. J., Fisher-Hoch, S. P., “Acute sensorineural deafness in Lassa fever.” JAMA 264(16): 2093-2096. Oct. 1990.
 
[19]  Bausch, D. G., Rollin, P. E., Demby, A. H., Coulibaly, M., Kanu, J., Conteh, A. S., Wagoner, K. D., McMullan, L. K., Bowen, M. D., Peters, C. J., Ksiazek, T. G., “Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation.” J Clin Microbiol 38(7): 2670-2677. Jul. 2000.
 
[20]  Asogun, D. A., Adomeh, D. I., Ehimuan, J., Odia, I., Hass, M., et al., “Molecular diagnostics for Lassa fever at Irrua specialist teaching hospital, Nigeria: Lessons learnt from two years of laboratory operation.” PLoS Negl Trop Dis. 6(9):e1839. Sep. 2012.
 
[21]  Lukashevich, I. S., “Advanced vaccine candidates for Lassa fever.” Viruses 4: 2514-2557. Oct. 2012.
 
[22]  Snoy, P.J., “Establishing efficacy of human products using animals” Veterinary Pathology Online 47: 774-778. Sep. 2010.
 
[23]  Goicocheaa, M.A., Zapata, J.C., Bryant, J., Davis, H., Salvato, M.S., Lukashevich, I.S., “Evaluation of Lassa virus vaccine immuno-genicity in a CBA/J–ML29 mouse model.” Vaccine 30: 1445-1452. Feb. 2012.
 
[24]  Robinson, M. C., “An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features.” Trans R Soc Trop Med Hyg 49(1): 28-32. Jan. 1955.
 
[25]  Lumsden, W. H., “An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53 II: General description and epidemiology.” Trans R Soc Trop Med Hyg 49: 33-57. Jan. 1955.
 
[26]  Chhabra, M., Mittal, V., Bhattacharya, D., Rana, U., Lal, S., “Chikungunya fever: A re-emerging viral infection.” Indian J Med Microbiol 26(1): 5-12. Jan. 2008.
 
[27]  Swiss Institute of Bioinformatics, “Viralzone: Alphavirus” Sep. 2016. Available: http://viralzone.expasy.org/viralzone/all_by_species/625.html [Accessed Sep 15 2016].
 
[28]  Powers, A. M., Logue, H. C., “Changing patterns of chikungunya virus: Re-emerging zoonotic arbovirus.” J Gen Virol 88(9): 2363-2377. May 2007.
 
[29]  Halstead, S. B., Nimmannitya, S., Margiotta, M. R., “Dengue and chikungunya virus infection in man in Thailand, 1962-1964, II: Observations on disease in outpatients.” Am J Trop Med Hyg 18: 972-783. Nov. 1969.
 
[30]  Centers for Disease Control, “Chikungunya fever among US Peace Corps Volunteers - Republic of the Philippines.” MMWR Morb Mortal Wkly Rep 35: 573-574. Sep. 1986.
 
[31]  Sarkar, J. K., Chatterjee, S. N., Chakravarty, S. K., “Haemorrhagic fever in Calcutta: Some epidemiological observations.” Indian J Med Res 52: 651-659. Jul. 1964.
 
[32]  Sharma, H. M., Shanmugham, C. A., Iyer, S.P., Rao, A. R., Kuppuswami, S. A., “Report on a random survey conducted to assess the prevalence of a dengue-like illness in Madras city - 1964.” Indian J Med Res 53: 720-728. Aug. 1965.
 
[33]  Staples, J. E., Breiman, R. F., Powers, A. M., “Chikungunya fever: An epidemiological review of a re-emerging infectious disease.” Clin Infect Dis 49: 942-948. Sep. 2009.
 
[34]  Sang, R. C., Ahmed, O., Faye, O., Kelly, C. L., Yahaya, A. A., et al., “Entomologic investigations of a chikungunya virus epidemic in the Union of the Comoros, 2005.” Am J Trop Med Hyg 78: 77-82. Jan. 2008.
 
[35]  Charrel, R. N., de Lamballerie, X., Raoult, D., “Chikungunya outbreaks - The globalization of vector borne diseases.” N Engl J Med 356(8): 769-771. Feb. 2007.
 
[36]  Lahariya, C., Pradhan, S. K., “Emergence of chikungunya virus in India subcontinent after 32 years: A review.” J Vect Borne Dis 43:151-160. Dec. 2006.
 
[37]  Angelini, R., Finarelli, A. C., Angelini, P., Po, C., Petropulacos, K., et al., “An outbreak of Chikungunya fever in the province of Ravenna, Italy.” Eurosurveillance. 12 (36): pii=3260. Sep. 2007.
 
[38]  Goffart, I. L., Nougairede, A., Cassadou, S., Prat, C., de Lamballerie, X., “Chikungunya in the Americas.” The Lancet 383:514. Feb. 2014.
 
[39]  Fischer, M., Staples, J. E., “Chikungunya virus spreads in the Americas -Caribbean and South America, 2013-2014.” CDC Morb Mortal Wkly Rep 63(22): 500-501. Jun. 2014.
 
[40]  Pfeffer, M., Linssen, B., Parke, M. D., Kinney, R. M., “Specific detection of chikungunya virus using a RT-PCR/nested PCR combination.” J Vet Med B Infect Dis Vet Public Health 49: 49-54. Feb. 2002.
 
[41]  Chu, H., Das, S. C., Fuchs, J. F., Suresh, M., Weaver, S. C., Stinchcomb, D. T., et al., “Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.” Vaccine: 31(33):3353-3360. Jul. 2013.
 
[42]  Hoen B., “Prevention of mother-to-child trans- mission of Chikungunya infection: Clinical evaluation of anti-CHIKV hyperimmune IVIg.” In: Gaps and opportunities in Chikungunya research: Expert consultation on Chikungunya disease in the Americas. [presentation] 11/03/2015; 2015. Available: https://respond.niaid.nih.gov/conferences/chikungunya/documents/9 hoen bruno modified.pdf.
 
[43]  World Health Organization, Regional Office for South-East Asia, “Guidelines for prevention and control of chikungunya fever.” WHO Library Cataloguing-in-Publication data. New Delhi, India. 2009.
 
[44]  Smalley, C., Erasmus J. H., Chesson C. B., Beasley D. W. C., “Status of research and development of vaccines for chikungunya” Vaccine 34: 2976-2981. Mar. 2016.
 
[45]  Weaver, S. C., Osorio J. E., Livengood J. A., Chen R, Stinchcomb D. T., “Chikungunya virus and prospects for a vaccine.” Expert Rev Vaccines 11(9): 1087-1101. Sep. 2012.
 
[46]  Edelman, R., Tacket, C. O., Wasserman, S. S., Bodison, S. A., Perry, J. G., Mangiafico, J. A., “Phase 2 safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.” Am. J. Trop. Med. Hyg. 62(6): 681–685. … 2000.
 
[47]  Gorchakov, R., Wang, E., Leal, G., et al. “Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein.” J. Virol. 86(11): 6084-6096. Jun. 2012.
 
[48]  Chang, L. J., Dowd, K. A., Mendoza, F. H., Saunders, J. G., Sitar, S., Plummer, S. H., et al. “Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial.” Lancet 384(9959): 2046-52. Dec. 2014.
 
[49]  Ramsauer, K., Schwameis, M., Firbas, C., Mullner, M., Putnak, R. J., Thomas, S. J., et al. “Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: A randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15(5): 519-27. May 2015.
 
[50]  Peters, C. J., LeDuc, J. W., “An introduction to Ebola: The virus and the disease.” J of Infect Dis 179(suppl.1): ix-xvi. Feb. 1999.
 
[51]  Swiss Institute of Bioinformatics, “Viralzone: Ebolavirus” Sep. 2016. Available: http://viralzone.expasy.org/viralzone/all_by_species/207.html [Accessed Sep 15 2016].
 
[52]  Johnson, K. M,, Lange, J. V., Webb, P. A., Murphy, F. A., “Isolation and characterization of a new virus (Ebola virus) causing acute hemorr-hagic fever in Zaire.” The Lancet 1: 569-571. Mar. 1977.
 
[53]  Rico, A., Brody, D., Coronado, F., Rondy, M., Fiebig, L., et al., “Epidemiology of epidemic Ebola virus disease in Conakry and surrounding Prefectures, Guinea, 2014-2015.” CDC. 22(2) Feb. 2016. Available: http://wwwnc.cdc.gov/eid/article/22/2/15-1304_article. [Accessed May 22 2016].
 
[54]  World Health Organization, “Emergencies preparedness, response. Origins of the 2014 Ebola epidemic. One year into the Ebola epidemic.” Jan. 2015. Available: http://www.who.int/csr/disease/ebola/one-year-report/virus-origin/en/ [Accessed May 21 2016].
 
[55]  Park, D. J., Dudas, G., Wohl, S., Goba, A., Whitmer, S. L., et al., “Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone.” Cell 161(7): 1516-1526. Jun. 2015.
 
[56]  World Health Organization, “Ebola virus disease.” Media centre Fact sheet No 103. Updated Jan. 2016. Available: http://www.who.int/mediacentre/factsheets/fs103/en/. [Accessed 21 May 2016].
 
[57]  King, J. W., Chandrasekar, P. H., “Ebola virus infection clinical presentation.” Medscape. Feb. 2015. Available: http://emedicine.medscape.com/article/216288-clinical [Accessed May 21 2016].
 
[58]  Saijo, M., Niikura, M., Ikegami, T., Kurane, T., Kurata, G. Morikawa, S., “Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins.” Clin Vaccine Immunol 13(4): 444-451. Apr. 2006.
 
[59]  World Health Organization, “Experimental therapies: Growing interest in the use of whole blood or plasma from recovered Ebola patients (convalescent therapies).” Media centre. Ebola situation assessment. Sep. 2014. Available: http://www.who.int/mediacentre/news/ebola/26-september-2014/en/ [Accessed Sep. 18 2016].
 
[60]  World Health Organization, “Ebola vaccines, therapies, and diagnostics.” Essential medicines and health products. Questions and Answers. Oct. 2015. Available: http://www.who.int/medicines/emp_ebola_q_as/en/. [Accessed Sep. 18 2016].
 
[61]  World Health Organization, “Experimental Ebola vaccines.” Ebola situation assessment. Media centre, Oct. 2014. Available: http://www.who.int/mediacentre/news/ebola/01-october-2014/en/ [Accessed Sep. 18 2016].
 
[62]  Agnandji, S.T., Huttner, A., Zinser M.E., Njuguna, P., Dahlke, C., et al., “Phase 1 trials of rVSV Ebola vaccine in Africa and Europe.” N Engl J Med 374: 1647-1660. Apr. 2016.
 
[63]  Tapia, M.D., Sow, S.O., Lyke K. E., Haidara F. C., Diallo, F., et al., “Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.” Lancet 16: 31-42. Jan. 2016.
 
[64]  Henao-Restrepo, A.M., Longini, I.M., Egger, M., Dean, N. E., et al., “Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.” www.thelancet.com Published online July 31, 2015.
 
[65]  Kuno, G., Chang, G-J., “Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses.” Arch Virol 152: 687-689. Jan. 2007.
 
[66]  Swiss Institute of Bioinformatics, “Viralzone: Zika virus” Sep. 2016. Available: http://viralzone.expasy.org/viralzone/all_by_species/6756.html. [Accessed Sep 15 2016].
 
[67]  Dick, G. W., Kitchen, S. F., Haddow, A. J., “Zika virus. I. Isolations and serological specificity.” Trans R Soc Trop Med Hyg 46:509-20. Sep. 1952.
 
[68]  MacNamara, F., “Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria.” Trans R Soc Trop Med Hyg 48:139-45. Mar. 1954.
 
[69]  Diallo, D., Sall, A. A, Diagne, C. T., Faye, O., Faye, O., et al., “Zika virus emergence in mosquitoes in southeastern Senegal, 2011.” PLoS One. 9:e109442. Oct. 2014.
 
[70]  Fagbami, A. H., “Zika virus infections in Nigeria: Virological and sero-epidemiological investigations in Oyo State.” J Hyg (Lond) 83(2):213-219. Oct. 1979.
 
[71]  Marchette, N., Garcia, R., Rudnick, A., “Isolation of Zika virus from Aedes aegypti mosquitoes in Malaysia”. Am J Trop Med Hyg 18: 411-415. May 1969.
 
[72]  Lanciotti, R. S., Kosoy, O. L., Laven, J. J,, Velez, J. O., Lambert, A. J., et al., “Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007.” Emerg Infect Dis 14: 1232-1239. Aug. 2008.
 
[73]  Cao-Lormeau, V. M., Roche, C., Teissier, A., Robin, E., Berry, A. L., et al., “Zika virus, French Polynesia, South Pacific, 2013.” Emerg Infect Dis 20: 1085-1086. Jun. 2014.
 
[74]  Alera, M. T., Hermann, L., Tac-An, I. A., Klungthong, C., Rutvisuttinunt, W., et al., “Zika virus infection, Philippines, 2012.” Emerg Infect Dis 21(4): 722-7242. Apr. 2015.
 
[75]  Zanluca, C., de Melo, V. C. A., Mosimann, A. L. P, dos Santos, G. I. V., dos Santos, C. N. D., Luz, K, “First report of autochthonous transmission of Zika virus in Brazil.” Mem Inst Oswaldo Cruz 110: 569-572. Jun. 2015.
 
[76]  Dyer, O.,”Zika virus spreads across America as concerns mount over birth defects.” BMJ.2015; h6983. Dec. 2015.
 
[77]  World Health Organization, “WHO Director-General summarizes the outcome of the Emergency Committee regarding clusters of microcephaly and Guillain-Barré syndrome.” Media centre Feb. 2016. Available: http://www.who.int/mediacentre/news/statements/2016/emergency-committee-zika-microcephaly/en/ [Accessed May 21 2016].
 
[78]  Centers for Disease Control, “Zika virus disease in the United States, 2015–2016.” Apr. 2016. Available: http://www.cdc.gov/zika/geo/united-states.html. [Accessed May 21 2016].
 
[79]  Centers for Disease Control, “Zika virus: Case counts in the US.” Sep. 2016. Available: http://www.cdc.gov/zika/geo/united-states.html. [Accessed Sep 19 2016].
 
[80]  Parreira, R., Centeno-Lima, S., Lopes, A., Portugal-Calisto, D., Constantino, A., Nina, J., “Dengue virus serotype 4 and chikungunya virus coinfection in a traveler returning from Luanda, Angola, January 2014.” Euro Surveill 19(10): pii=20730. Mar. 2014.
 
[81]  Song, J., Mauk, M.G., Hackett, B.A., Cherry, S., Bau, H.H., Liu, C., “Instrument-free point-of-care molecular detection of Zika virus.” Anal. Chem. 2016, 88: 7289-7294. Jun. 2016.
 
[82]  Pardee, K., Green, A. A., Takahashi, M. K., Braff, D., Lambert, G., et al., “Rapid, low-cost detection of Zika virus sing programmable biomolecular components.” Cell 165: 1255-1266. May 2016.
 
[83]  Dawes, B.E., Smalley, C. A., Tiner, B. L., Beasley, D.W.C., Mil, G. N., “Research and development of Zika virus vaccines.” npj Vaccines 1: 16007. Jul. 2016.
 
[84]  Abbink, P., Larocca, R.A., De La Barrera, R. A., Bricault, C. A., Moseley E. T., et al. “Protective efficacy of multiple platforms against Zika virus challenge in rhesus monkeys.” Science 10.1126/science.aah6157. Aug. 2016.
 
[85]  National Institute of Health, “NIH begins testing investigational Zika vaccine in humans.” News Releases. Available: https://www.nih.gov/news-events/news-releases/nih-begins-testing-investigational-zika-vaccine-humans Aug. 2016. [Accessed Sep. 18 2016].
 
[86]  novio Pharmaceuticals, “Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial.” Globe Newswire, Jul. 2016. Available: http://ir.inovio.com/news/news-releases/news-releases-details/2016/Inovio-Pharmaceuticals-Doses-First-Subject-in-Zika-Vaccine-Clinical-Trial/default.aspx. [Accessed Sep 20 2016].
 
[87]  Xu, M., Lee, E. M., Wen, Z., Cheng, Y., Huang, W. K., et al. “Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.” Nat Med. 2016 Aug 29.
 
[88]  Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., et al., “A screen of FDA-approved drugs for inhibitors of Zika virus infection.” Cell Host Microbe 20(2): 259-270. Jul. 2016.
 
[89]  Nunes, J., “Ebola and the production of neglect in global health.” Third World Quarterly 37:542-556. Mar. 2016.
 
[90]  Broadhurst, M. J., Kelly, J. D., Miller, A., Semper, A., Bailey, D., et al., “ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study.” Lancet 386(9996): 867-874. Jun. 2015.
 
[91]  Yang, M., Ke, Y., Wang, X., Ren, H., Liu, W., et al., “Development and evaluation of a rapid and sensitive EBOV-RPA test for rapid diagnosis of Ebola virus disease.” Sci. Rep. 6: 26943. Jun. 2016.
 
[92]  Enserink M. “Debate erupts on repurposed drugs for Ebola.” Science 345: 718-719. Aug. 2014.
 
[93]  Sweiti, H., Ekwunife, O., Jaschinski,T., Lhachimi, S. K., “Repurposed therapeutic agents targeting the Ebola virus: A protocol for a systematic review.” Systematic Reviews 4:171- Nov. 2015.
 
[94]  Tang, H., Hammack, C., Ogden, S. C., Wen, Z., Qian X., et al. “Zika virus infects human cortical neural progenitors and attenuates their growth.” Cell Stem Cell 18: 587-590. May 2016.
 
[95]  Rossi, S. L., Tesh, R. B., Azar, S. R., Muruato, A. E., Hanley, K. A., et al. “Characterization of a novel murine model to study Zika virus.” Am. J. Trop. Med. Hyg. 94: 1362-1369. Mar. 2016.
 
[96]  Li, C., Xu, D., Ye, Q., Hong S., Jiang Y., et al. “Zika virus disrupts neural progenitor development and leads to microcephaly in mice.” Cell Stem Cell 19: 120-126. Jul 2016.
 
[97]  Driggers, R.W., Ho, C.-Y., Korhonen, E.M. Kuivanen, S., Jääskeläinen A.J., et al. “Zika virus infection with prolonged maternal viremia and fetal brain abnormalities.” N. Engl. J. Med. 374: 2142-2151 Jun. 2016.
 
[98]  Qian, X., Nguyen, H. N., Song, M. M., Hadiono, C., Ogden, S. C., et al. “Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure.” Cell 165: 1238-1254. May 2016.
 
[99]  Dang, J., Tiwari, S.K., Lichinchi, G., Qin, Y., Patil V. S., et al. “Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3.” Cell Stem Cell 19: 258-265. Jul. 2016.
 
Manuscript template